As of Wednesday, Germany will limit the use of the astrogenogenic vaccine against Govt-19, which is only available to people aged 60 and over and high priority groups, following reports of a rare brain hemorrhage.
“We must rely on vaccines,” German Chancellor Angela Merkel told reporters at a news conference on Tuesday. “And transparency is the best way to deal with a situation like this,” he added.
On the recommendation of the German Immunization Committee, known as STIKO, state and federal health ministers agreed that people under the age of 60 should be vaccinated with the estrogen vaccine only if they belong to a higher priority group, which includes high-risk patients and health professionals, after consultation with a physician.
Those under the age of 60 who have already received the first dose of AstraZeneca will have the opportunity to receive the second dose as planned, if they are in the priority group, or wait for the next vaccination group recommendation, which is expected in late April.
The new regulation on the use of the astrogenic vaccine is another setback in Germany’s already long vaccination campaign.
Previously, the group recommended that it be used only for those 60 and older “according to available data on rare, but very serious, thromboembolic side effects.”
STIKO is also exploring the possibility of administering a second drug through a different vaccine.
In a note responding to the panel’s recommendation, AstraZeneca stated that patient safety was its highest priority and pointed out that medical agents in Europe and the United Kingdom could not establish a causal relationship between vaccine and blood clot formation. …
“We will continue to work with the German authorities to answer any questions,” the pharmacist said.
However, Germany will allow people 60 years of age and older to take AstraZeneca in an effort to speed up their vaccination campaign.
So far, the country has only vaccinated people over the age of 70 and high priority groups.
The German government’s decision follows reports of cases of cerebral venous thrombosis (DVC) from the Paul Ehrlich Institute, the country’s vaccine regulatory agency.
Of the approximately 2.7 million people who have been vaccinated with AstraZeneca, 31 cases of CVD have been reported, resulting in 9 deaths, the company said. With the exception of two cases, all cases were reported in women aged 20 to 63 years.
Reuters – This publication, which includes information and data, is Reuters’ intellectual property. It is explicitly forbidden to use it or your name without the prior approval of Reuters. All rights reserved.